Key statistics
On Monday, Hansa Biopharma AB (24H:DUS) closed at 2.97, -24.44% below its 52-week high of 3.93, set on Feb 12, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 3.06 |
|---|---|
| High | 3.06 |
| Low | 2.97 |
| Bid | 2.93 |
| Offer | 3.05 |
| Previous close | 3.11 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 101.76m |
| Free float | 48.58m |
| P/E (TTM) | -- |
| Market cap | 3.44bn SEK |
| EPS (TTM) | -6.44 SEK |
Data delayed at least 15 minutes, as of Mar 02 2026 18:32 GMT.
More ▼
Press releases
- Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA
- Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA
- Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
- Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
- Hansa Biopharma has won the 2025 SwedenBIO Award
- Hansa Biopharma has won the 2025 SwedenBIO Award
- Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
- Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
More ▼
